CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade: Molecular Therapy - Nucleic Acids
Frontiers | Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity
Frontiers | The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Tumour-intrinsic resistance to immune checkpoint blockade | Nature Reviews Immunology
Dendritic cells in cancer immunology | Cellular & Molecular Immunology
Cancers | Free Full-Text | Recent Advances and Challenges in Cancer Immunotherapy
Molecular and cellular insights into T cell exhaustion | Nature Reviews Immunology
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Nature Reviews Clinical Oncology
DNA Damage Signaling to Immune Checkpoints
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Nature Reviews Cancer
Immune cell promotion of metastasis | Nature Reviews Immunology
Biology | Free Full-Text | Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
The blockade of immune checkpoints in cancer immunotherapy | Nature Reviews Cancer
Frontiers | The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Regulatory circuits of T cell function in cancer | Nature Reviews Immunology
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies | Nature Reviews Endocrinology
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications | Cellular & Molecular Immunology
Frontiers | What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Mechanisms of resistance to immune checkpoint inhibitors | British Journal of Cancer
The blockade of immune checkpoints in cancer immunotherapy | Nature Reviews Cancer
Cells | Free Full-Text | Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Adoptive immunotherapy for cancer: harnessing the T cell response | Nature Reviews Immunology
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges: Molecular Therapy - Oncolytics
Cancer immunotherapy via dendritic cells | Nature Reviews Cancer
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Bystander T cells in cancer immunology and therapy | Nature Cancer
Targeting neoantigens to augment antitumour immunity | Nature Reviews Cancer
